JUMP REPORT
| Avg Daily Volume: 1,291,993 Market Cap: 10.95B Sector: Healthcare Short Interest: 1.42 |
EARNINGS EXPECTATIONS:
THIS QTR: EPS: .75/share REV: 1, 090/M
___________________________________________________________
LAST QTR: EPS: .50/share ACTUAL: .57/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: .56/share REV: 975.9/M
______________________________________________________
FULL YR: EPS: 2.46/share REV: 4,000/M
______________________________________________________
*These are the base metrics we will be watching against the actual release numbers
______________________________________________________
BEAT/MISS RECORD: 53% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 8.2, -7.74, 8.5
EXPECTED JUMP MOVE: 10%
Links To Latest News and Headlines
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
DENTSPLY SIRONA’s (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.
On Wednesday, Dentsply Sirona Inc (NASDAQ: XRAY) announced interim FY22 sales above the high end of the company’s prior outlook range of $3.85 billion to $3.88 billion. FY22 adjusted EPS is expected to be within the company’s prior outlook range of $1.90 to $2.00. William Blair writes that this was a welcomed preannouncement that shows a stabilizing organization after several quarters of declining EPS expectations. Management also provided additional high-level details around long-term strategy
Shares of Dentsply Sirona Inc. (XRAY) climbed 1.0% in premarket trading Wednesday, after the dental products maker provided an upbeat full-year revenue outlook. The company, which is presenting at the J.P. Morgan Healthcare Conference Wednesday morning, said it expects 2022 sales to be “above the high end” of its previous guidance of $3.85 billion to $3.88 billion.
CHARLOTTE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 10:30 am PT (1:30 pm ET). As part of the conference, the Company is providing an update on its anticipated financial results with net sales expected to be above the high end of the Company’s prior outlook range of $3.85 billion to $3.88 billion. Full year 2022 adjusted EPS i
StockJumpers analysis and trade plans are uploaded generally 1 HOUR BEFORE MARKETS CLOSE (3PM EST) for most events.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is striped down to only what it needed to make the best possible decision(s) on trading the trajectory.
NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.